Dubai Science Park, the region’s leading science-focused ecosystem and part of TECOM Group PJSC, convened the DSP Leadership Network Forum in partnership with Emirates Drug Establishment (EDE), bringing together leaders from government, healthcare and industry to discuss pharmaceutical resilience and innovation in the UAE.

The DSP Leadership Network Forum explored opportunities to strengthen collaboration and accelerate access to innovative medical and pharmaceutical products in line with the UAE’s vision to strengthen its position as a global hub for pharmaceutical and medical industries.

The forum featured a panel discussion titled “Building an Unbreakable Chain: Pharma Resilience Across UAE’s Ecosystem,” with participation from leaders representing regulation, healthcare, and the pharmaceutical industry. Chaired by Marwan Abdulaziz Janahi, Senior Vice President of Dubai Science Park, the panel included Dr. Ruqaya Aqeel Al Bastaki, Medical Products Regulation Sector Lead at the Emirates Drug Establishment (EDE); Sameh El Fangary, Country President – Gulf Cluster at AstraZeneca; and Dr. Heidar Arjomand, Group Chief Medical Officer at American Hospital Dubai.

“Strengthening pharmaceutical resilience requires meaningful collaboration across the entire healthcare ecosystem,” said Marwan Abdulaziz Janahi, Senior Vice President of Dubai Science Park, part of TECOM Group. “Through our partnership with Emirates Drug Establishment, this forum brought together key stakeholders from across the pharmaceutical ecosystem to address shared priorities, exchange insights and support continued innovation. As the home of the UAE’s life sciences ecosystem, Dubai Science Park will continue its pivotal role in fostering strategic partnerships and knowledge exchange that advance scientific progress, strengthen preparedness, and contribute to national priorities in line with the ‘We the UAE 2031’ and the ‘UAE Centennial 2071’ visions.”

Participants also discussed the UAE’s growing role as a global hub for pharmaceutical and healthcare innovation and the role of agile and streamlined regulatory framework that champions domestic R&D and accelerates patient access to innovative medical and pharmaceutical products developed in the UAE.

The discussions also highlighted examples of innovation being advanced through collaboration between regulators and industry. Companies such as AstraZeneca, part of Dubai Science Park’s life sciences community, continue to contribute to the UAE’s healthcare innovation ecosystem by helping bring advanced products to patients and supporting the country’s vision of providing world-class healthcare.

Participants highlighted the UAE’s strategic advantages as a regional logistics hub and its robust pharmaceutical supply chain, which support long-term sector growth. Participants emphasised the importance of continued alignment between regulators, manufacturers, healthcare providers and researchers in advancing pharmaceutical innovation and industry growth.

The DSP Leadership Network is a platform built by Dubai Science Park to convene its community of senior leaders across the healthcare, life sciences, energy and environmental sciences ecosystem, bringing together influential voices in the UAE to drive collaboration, knowledge exchange and science-led progress.

Dubai Science Park is part of TECOM Group’s portfolio of business districts, which includes Dubai Internet City, Dubai Media City, Dubai Production City, Dubai Studio City, Dubai International Academic City, Dubai Knowledge Park, Dubai Design District (d3), and Dubai Industrial City.